ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,559Medicare Part D Prescriptions Filled, Including Refills

Rank: 517 out of 3593

$628K Total Retail Price of All Prescriptions

Rank: 396 out of 3593

426 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

5% of this provider’s 426 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

1% of this provider’s 8,755 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$59 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
AMLODIPINE BESYLATE 522 470 1 3
SIMVASTATIN 472 424 2 1
LEVOTHYROXINE SODIUM 352 322 3 4
OMEPRAZOLE 338 236 4 5
PRAVASTATIN SODIUM 280 239 5 13
RAMIPRIL 249 198 6 92
LISINOPRIL 247 183 7 2
CARVEDILOL 228 169 8 23
CLONIDINE HCL 216 186 9 41
CRESTOR 212 181 10 21
ATORVASTATIN CALCIUM 197 172 11 15
METOPROLOL SUCCINATE 183 177 12 19
LOSARTAN POTASSIUM 182 166 13 14
ALLOPURINOL 173 154 14 35
TRAMADOL HCL 160 122 15 17
ZETIA 149 135 16 110
FUROSEMIDE 135 121 17 9
HYDROCHLOROTHIAZIDE 131 112 18 10
QUINAPRIL HCL 124 106 19 219
GLIMEPIRIDE 123 102 20 44
METFORMIN HCL 120 83 21 6
SPIRONOLACTONE-HCTZ 115 104 22 329
METOPROLOL TARTRATE 110 101 23 8
ALENDRONATE SODIUM 106 99 24 22
FAMOTIDINE 106 88 24 70
TAMSULOSIN HCL 97 82 26 33
HYDRALAZINE HCL 97 65 26 107
LISINOPRIL-HYDROCHLOROTHIAZIDE 96 87 28 26
NIFEDIPINE ER 94 82 29 75
CLOPIDOGREL 90 86 30 30
TRILIPIX 81 70 31 233
ENALAPRIL MALEATE 80 80 32 38
TRIAMTERENE-HCTZ 73 55 33 66
PROAIR HFA 72 46 34 54
RANITIDINE HCL 71 66 35 27
GABAPENTIN 71 57 35 16
CIPROFLOXACIN HCL 68 59 37 52
NEXIUM 67 39 38 36
PLAVIX 67 63 38 42
WELCHOL 64 51 40 285
DIOVAN 63 63 41 46
LOVAZA 63 49 41 106
CITALOPRAM HBR 61 59 43 25
WARFARIN SODIUM 59 51 44 18
FLUTICASONE PROPIONATE 57 50 45 32
POTASSIUM CHLORIDE 55 41 46 24
DIOVAN HCT 55 55 46 76
ATENOLOL 54 41 48 11
METFORMIN HCL ER 52 40 49 67
AZITHROMYCIN 52 41 49 34
DONEPEZIL HCL 51 51 51 31
INSULIN SYRINGE 50 21 52 91
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.